替格瑞洛联合替罗非班治疗急性心肌梗死的临床效果

Clinical Efficacy of Ticagrelor Combined with Tirofiban in the Treatment of Acute Myocardial Infarction

目的 探讨替格瑞洛联合替罗非班治疗急性心肌梗死的临床效果。方法 方便选取2021年1月—2023年12月福建省霞浦县医院收治的52例急性心肌梗死(acute myocardial infarction, AMI)患者为研究对象,根据不同用药方案分为对照组和观察组,各26例。两组患者均给予常规药物治疗,在此基础上,对照组使用替罗非班治疗,观察组使用替格瑞洛联合替罗非班治疗,对比两组患者的临床疗效、心功能、炎性因子水平、血小板指标、并发症发生情况。结果 观察组治疗总有效率为96.15%(25/26),高于对照组的73.08%(19/26),差异有统计学意义(χ^(2)=5.318,P<0.05)。治疗后,观察组左心室射血分数(left ventricular ejection fractions, LVEF)、每搏输出量(stroke volume, SV)均高于对照组,左心室舒张末期容积(left ventricular end-diastolic volume,LVEDV)、左心室收缩末期容积(left ventricular systolic volume, LVESV)均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组血小板聚集率、血小板计数(platelets, PLT)、C-反应蛋白(C-reactive protein, CRP)、白介素-6(interleukin-6, IL-6)水平均低于对照组,差异有统计学意义(P均<0.05)。观察组并发症总发生率低于对照组,差异有统计学意义(P<0.05)。结论 替格瑞洛联合替罗非班治疗AMI的临床效果显著,能有效降低血小板聚集率,减轻炎症反应,改善心功能,降低并发症风险。

Objective To investigate the clinical effect of ticagrelor combined with tirofiban in the treatment of acute myocardial infarction.Methods A total of 52 patients with acute myocardial infarction(AMI)admitted to Xiapu County Hospital of Fujian Province from January 2021 to December 2023 were conveniently selected as the research subjects and divided into control group and observation group according to different medication regimens,with 26 cases in each group.Both groups were treated with conventional drugs.On this basis,the control group was treated with tirofiban,and the observation group was treated with ticagrelor combined with tirofiban.The clinical efficacy,cardiac function,inflammatory factor levels,platelet indexes and complications were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.15%(25/26),which was higher than 73.08%(19/26)in the control group,and the difference was statistically significant(χ^(2)=5.318,P<0.05).After treatment,the left ventricular ejection fractions(LVEF)and stroke volume(SV)in the observation group were higher than those in the control group,and the left ventricular end-diastolic volume(LVEDV)and left ventricular systolic volume(LVESV)were lower than those in the control group,the differences were statistically significant(all P<0.05).After treatment,levels of the platelet aggregation rate,platelets(PLT),C-reactive protein(CRP)and interleukin-6(IL-6)in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The total incidence of complications in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion Ticagrelor combined with tirofiban has a significant clinical effect in the treatment of AMI,which can effectively reduce platelet aggregation rate,reduce inflammation,improve cardiac function and reduce the risk of complications.